ClinicalTrials.gg
RecruitingNCT06656689Updated Nov 6, 2024

Study on Water Vapor Thermal Therapy

An observational study in Benign Prostatic Hyperplasia, sponsored by Saint Vincent's Hospital, Korea. Recruiting at 1 site in Korea, Republic of. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Saint Vincent's Hospital, Korea · Observational

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.

Planned enrollment
8th of 15
300 · median 300
Started
2023
with 2 others
Observational
15 of 72
2 open now
Registered
65th of 72
by date

Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2023, is one of 15 observational ones, and was the 65th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the efficacy of Rezum water vapor thermal therapy in benign prostatic hyperplasia patients. The main question it aims to answer is:

  • Is Rezum an effective treatment?
  • Is Rezum safe?

Participants will be followed up for at least three months after the treatment to evaluate efficacy and safety.

Read the detailed description

This prospective cohort study aims to evaluate the safety and efficacy of the Rezum procedure, a minimally invasive treatment for benign prostatic hyperplasia (BPH) that utilizes convective water vapor thermal energy. The Rezum procedure was approved by the U.S. FDA in 2015, and recent approval by South Korea's Ministry of Health and Welfare has allowed its use in South Korean patients. Unlike other BPH treatments, Rezum delivers steam at 103°C directly into the prostatic tissue, inducing necrosis and reduction of prostate size through a controlled thermal effect. This process is conducted in a day-surgery setting under local, general, or spinal anesthesia, minimizing patient burden and recovery time.

The study will enroll male patients aged 50 or older with confirmed BPH who meet specific prostate size criteria, measured via transrectal ultrasound. Following a preoperative evaluation, including prostate size, PSA levels, symptom questionnaires, and urodynamic assessment, patients will undergo the Rezum procedure. This involves cystoscope-guided needle insertion into hypertrophic prostate regions, where targeted thermal energy is delivered in short bursts. The procedure is completed within a single hospital visit, and patients are generally discharged on the same day unless complications arise.

After surgery, participants will have routine follow-up visits, including catheter removal and initial voiding assessments within one week. Further follow-up, at a minimum of three months, will include standardized assessments of voiding function, symptom severity (IPSS, IIEF, OAB-q), prostate size, uroflowmetry, and residual urine volume. The safety profile will be assessed by recording adverse events, including infection, hematuria, voiding dysfunction, and the necessity for catheter reinsertion. Complications will be classified according to the Clavien-Dindo classification system.

Data analysis will assess the preoperative and postoperative changes in symptom severity, functional parameters, and prostate measurements. Comparisons of these continuous variables will utilize paired sample t-tests or Wilcoxon signed-rank tests, depending on normality test results. Variables include IPSS, IIEF, OAB-q, prostate size, PSA, maximum flow rate (Qmax), and post-void residual volume (PVR). Additionally, multiple regression analysis will identify factors contributing to the need for postoperative catheter reinsertion. Statistical significance will be set at α=0.05, with p-values below 0.05 indicating significant differences.

This study will address a current gap in research on the Rezum procedure's impact on Korean patients, contributing to the understanding of this minimally invasive approach within different populations and expanding its potential applicability.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia
  • Rezum
  • Water Vapor Thermal Therapy
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study subjects are patients requiring surgery for benign prostatic hyperplasia (BPH).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 or older
  • Prostate size between 30cc and 80cc as measured by transrectal ultrasound
  • Patients scheduled for Rezum surgery for BPH

Exclusion criteria

Exclusion Criteria:

  • Suspected prostate cancer
  • Suspected urinary tract infection
  • Inability to complete follow-up
  • Patients who do not consent to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Rezum Group

    Patients who underwent Rezum water vapor thermal therapy treatment for BPH

    Procedure: Rezum (water vapor thermal therapy)

Interventions

  • ProcedureRezum (water vapor thermal therapy)

    Rezum or water vapor thermal therapy is a procedure that involves injecting steam at 103°C into the prostate tissue to induce necrosis and reduce the size of the enlarged prostate.

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score (IPSS)

    International Prostate Symptom Score (IPSS) is a validated, reproducible scoring system to assess disease severity and response to therapy for BPH. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

    Time frame: From enrollment to three months after treatment

  2. Qmax

    Maximal urine flow rate in uroflowmetry exam

    Time frame: From enrollment to three months after treatment

Secondary outcomes

  1. Complications

    Complications evaluated using the Clavien-Dindo classification

    Time frame: Three months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, Pliskin M, Beahrs JR, Prall D, Kaminetsky J, Cowan BE, Cantrill CH, Mynderse LA, Ulchaker JC, Tadros NN, Gange SN, Roehrborn CG. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021 Sep;206(3):715-724. doi: 10.1097/JU.0000000000001778. Epub 2021 Apr 19. PubMed 33872051 ↗

Individual participant data

Plan to share: Undecided — IPD will be shared upon reasonable request to the PI. The investigators do not have a specific URL to provide the information.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.

Of 59 non-industry observational studies under Prostatic Hyperplasia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 60 months is above that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 24, 2024
StartActual
Jul 31, 2023
Primary completionEst.
Jul 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06656689
Lead sponsor
Saint Vincent's Hospital, Korea
Responsible party
Hee Youn Kim (Associate Professor, Saint Vincent's Hospital, Korea) — Principal investigator
First posted
Oct 24, 2024
Start date
Jul 31, 2023
Primary completion
Jul 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 6, 2024

Study contacts

Hee Youn Kim, M.D., Ph.D.
Contact
khyoun10589@gmail.com
82-10-9024-6533
Seung-Ju Lee, M.D., Ph.D.
Contact
seungju@catholic.ac.kr
82-10-5910-7278
Hee Youn Kim, M.D., Ph.D.
principal investigator · St Vincent's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion